Wantstats
Company ProfilePremium

Cara Therapeutics, Inc

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Cara Therapeutics, Inc - Healthcare showcase

Year Founded & Workforce

2004

50 Employees

Industry

Healthcare

Services

Medical Cannabis Market
C

Cara Therapeutics, Inc Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Cara Therapeutics, Inc Overview

Company Headquarter: Connecticut, US

Founded: 2004

Workforce: ~50

Company Working: Cara Therapeutics, Inc. is an emerging biotechnology company that develops novel therapeutics to treat pain, inflammation, and pruritus. It is a clinical-stage biotechnology company working on cannabinoid receptors to develop alternative treatment solutions for patients. The company’s advanced patented compound CR845 is undergoing various clinical tests for uremic pruritus and acute pain. Cara Therapeutics, Inc. has a group of medical experts, scientists, and industry leaders helping in providing innovative solutions to patients.

Strategy

Cara Therapeutics, Inc. focuses on research and development activities to launch new innovative products in the market. It is working with medical experts and scientists to develop quality products that can fulfill customer demands. The company’s customer-oriented approach will help the company gain a strong customer base in the future.

Company Snapshot

$198.9M

Revenue

50

Employees

2004

Founded

SWOT Analysis

Strengths

  • Strong R&D to focus to develop innovative products
  • Strong workforce of medical experts and scientists

Weaknesses

  • Most of the products are in various stages of the clinical trials

Opportunities

  • High demand for innovative products from end-users
  • Unmet medical needs in developing and underdeveloped regions

Threats

  • Growing competition from other companies
  • Stringent political and regulatory environment

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
September 2022AnnouncementCara Therapeutics, Inc. announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. (Japan) submitted to Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients.
April 2021AnnouncementCara Therapeutics, Inc. announced topline results from its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA (difelikefalin tablets) to treat moderate-to-severe pruritus in mild-to-severe atopic dermatitis (AD) patients.
May 2018AgreementCara Therapeutics, Inc. signed an agreement of USD 540 million with Fresenius (Germany) and Vifor Pharma (Switzerland) in order to commercialize the Korsuva.

Product Offering

  • Cara Therapeutics, Inc
    • Medical Cannabis Market

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 198.9 Mn in 2019 to USD 23 Mn in 2021.
Cara Therapeutics, Inc — By Business Segment
Series (USD Mn)201920202021
Sales198.9135.123
R&D Expenditure113.8107.982.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →